로딩 중…
지수 로딩 중…
Enanta Pharmaceuticals, Inc.
ENTA· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$12.95+2.78%
2026-08-03
Financials
Valuation Metrics
Enanta Pharmaceuticals, Inc.'s Market Cap is $377M. At end of 2025 it was $337M. Ranked #2903 of 3,112 in US market (top 93%), #1286 of 1,445 on NASDAQ (top 89%), #233 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 87%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $377M | US#2,903/3,112 Sec#233/269 |
| Revenue | $69M | US#2,838/3,112 Sec#144/269 |
| Net Income | $-62M | US—/3,112 Sec—/269 |
| Total Assets | $315M | US#2,883/3,112 Sec#205/269 |
| Net Assets | $117M | US#2,861/3,112 Sec#222/269 |
| Value | ||
| P/B | 3.23x | US#1,760/3,112 Sec#94/269 |
| P/S | 5.44x | US#2,328/3,112 Sec#85/269 |
| FCF Yield | -2.55% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | -53.17% | US#2,753/3,112 Sec#179/269 |
| ROA | -19.70% | US#2,769/3,112 Sec#125/269 |
| Op. Margin | -87.24% | US#2,815/3,112 Sec#121/269 |
| Revenue Growth | 14.96% | US#969/3,112 Sec#84/269 |
| Financial Health | ||
| Debt Ratio | 169.93% | US#1,627/3,112 Sec#192/269 |
| Total Debt | $187M | US#2,216/3,112 Sec#97/269 |
| FCF | $-10M | US#2,326/3,112 Sec#89/269 |
| Cash | $35M | US#2,722/3,112 Sec#245/269 |
| Current Ratio | 3.84x | US#607/3,112 Sec#171/269 |
| Performance | ||
| 1Y Return | 82.14% | US#405/3,112 Sec#92/269 |
| 1M Return | -14.30% | US#2,785/3,112 Sec#197/269 |
| From 52W High | -24.49% | US#1,919/3,112 Sec#135/269 |
| 1Y MDD | -34.30% | US#1,653/3,112 Sec#107/269 |
| Trading | ||
| Volume | 161,619 shares | US#2,765/3,112 Sec#255/269 |
| Trading Value | $2M | US#2,912/3,112 Sec#243/269 |
| Per Share | ||
| EPS | $-3.35 | US—/3,112 Sec—/269 |
| BPS | $5.92 | US#2,141/3,112 Sec#117/269 |